Heska Corp (HSKA) Stake Lowered by Bank of New York Mellon Corp
Bank of New York Mellon Corp cut its holdings in Heska Corp (NASDAQ:HSKA) by 9.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 87,120 shares of the medical research company’s stock after selling 8,596 shares during the quarter. Bank of New York Mellon Corp owned 1.15% of Heska worth $7,501,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of the company. BlackRock Inc. increased its position in Heska by 0.8% during the fourth quarter. BlackRock Inc. now owns 1,075,438 shares of the medical research company’s stock worth $92,596,000 after buying an additional 8,460 shares in the last quarter. California Public Employees Retirement System increased its position in Heska by 19.0% during the fourth quarter. California Public Employees Retirement System now owns 8,642 shares of the medical research company’s stock worth $744,000 after buying an additional 1,381 shares in the last quarter. Oregon Public Employees Retirement Fund purchased a new position in Heska during the fourth quarter worth $224,000. WINTON GROUP Ltd increased its position in Heska by 9.2% during the fourth quarter. WINTON GROUP Ltd now owns 6,075 shares of the medical research company’s stock worth $523,000 after buying an additional 513 shares in the last quarter. Finally, Tygh Capital Management Inc. increased its position in Heska by 8.8% during the fourth quarter. Tygh Capital Management Inc. now owns 31,771 shares of the medical research company’s stock worth $2,735,000 after buying an additional 2,575 shares in the last quarter. Institutional investors and hedge funds own 84.72% of the company’s stock.
Several equities analysts have weighed in on the company. BidaskClub downgraded Heska from a “hold” rating to a “sell” rating in a research report on Friday, April 5th. Zacks Investment Research downgraded Heska from a “buy” rating to a “hold” rating in a research report on Friday, February 8th. B. Riley dropped their price target on Heska from $93.00 to $87.00 and set a “neutral” rating for the company in a research report on Wednesday, February 27th. Finally, Benchmark downgraded Heska from a “buy” rating to a “hold” rating in a research report on Wednesday, February 27th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $109.00.
Heska (NASDAQ:HSKA) last announced its quarterly earnings data on Tuesday, February 26th. The medical research company reported $0.44 EPS for the quarter, missing the Zacks’ consensus estimate of $0.76 by ($0.32). Heska had a net margin of 4.59% and a return on equity of 9.87%.
In other news, COO Jason A. Napolitano sold 4,829 shares of Heska stock in a transaction on Wednesday, January 16th. The stock was sold at an average price of $90.91, for a total value of $439,004.39. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders sold 27,329 shares of company stock valued at $2,638,829. Company insiders own 14.00% of the company’s stock.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
Featured Article: How is inflation measured?
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.